Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Molecular structure and application of tumor necrosis factor receptor 1 proligand assembly domain glycocluster

A tumor necrosis factor and conjugate technology, applied in the field of tumor necrosis factor receptor 1 pro-ligand assembly domain protein conjugates, can solve the problems of indistinguishability, increased incidence of lymphoma, inability to distinguish multiple TNFR pathways, etc.

Inactive Publication Date: 2011-10-05
CHINA PHARM UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since this TNFα-targeted treatment method cannot distinguish between multiple TNFR pathways, such as the combination of TNFα and TNFR1 and TNFR2, it will also inhibit the physiological effects mediated by TNFR2 when inhibiting TNFR1-induced diseases, which may Causes side effects such as lupus-like disease, mycobacterial infection, and increased incidence of lymphoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular structure and application of tumor necrosis factor receptor 1 proligand assembly domain glycocluster
  • Molecular structure and application of tumor necrosis factor receptor 1 proligand assembly domain glycocluster
  • Molecular structure and application of tumor necrosis factor receptor 1 proligand assembly domain glycocluster

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Coupling of mPEG-aldehyde to the N-terminal α-amino group of PLAD (SEQ ID NO: 1, Xaa=Leu)

[0031]Use 20mM acetic acid-sodium acetate buffer to configure PLAD into a protein solution of 10mg / ml, pH5.2, and add methoxypolyethylene glycol with a molecular weight of 20000Da using 20mM acetic acid-sodium acetate buffer Aldehyde (mPEG-ALD20000), so that the molar ratio of protein to PEG is 1:1, and sodium cyanoborocyanide at a final concentration of 20 mM is added to catalyze the reduction reaction. Leave to react at 4°C for 16 hours. After the reaction, dilute the reaction solution and adjust the pH value to neutral to stop the reaction. The reaction proceeds according to the following reaction formula:

[0032]

Embodiment 2

[0034] mPEG-maleimide coupled to Cys at the end of PLAD (SEQ ID NO: 2, Xaa=Cys)

[0035] Use 20mM Tris-HCl buffer to configure PLAD into a 6mg / ml, pH8.0 protein solution, add 2000Da methoxypolyethylene glycol maleyl with a molecular weight of 20mM Tris-HCl buffer imine (mPEG-MAL2000) such that the molar ratio of protein to PEG was 1:1. Leave to react at 4°C for more than 6 hours.

[0036] The reaction proceeds according to the following reaction formula:

[0037]

Embodiment 3

[0039] Coupling of mPEG-vinylsulfone to Cys at the end of PLAD (SEQ ID NO: 3, Xaa=Cys)

[0040] Use 20mM Tris-HCl buffer to configure PLAD into a 6mg / ml, pH 8.0 protein solution, add 5000Da methoxypolyethylene glycol vinyl sulfone with a molecular weight of 20mM Tris-HCl buffer (mPEG-VS5000) such that the molar ratio of protein to PEG was 1:2. Leave to react at 4°C for more than 6 hours. The reaction proceeds according to the following reaction formula:

[0041]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biotechnology and specially relates to a molecular structure, a preparation method and an application of a tumor necrosis factor receptor 1 proligand assembly domain glycocluster. A proligand assembly domain (PLAD) of a tumor necrosis factor receptor 1 and molecules of polyethylene glycol (PEG) and the like are connected through covalent bonds to form a tumor necrosis factor receptor 1 proligand assembly domain protein glycocluster molecule, wherein the PLAD part can be prepared through a technology of protein recombinant and expression. The invention aims at obtaining a PLAD molecule with a long serum half-life period and the PLAD molecule is utilized for treating human inflammatory diseases.

Description

technical field [0001] The invention belongs to the field of biotechnology and relates to a tumor necrosis factor receptor 1 pro-ligand assembly domain protein conjugate. Background technique [0002] The extracellular region of tumor necrosis factor receptor (TNFR) superfamily is mainly responsible for ligand recognition and binding, and their extracellular region usually contains 1 to 6 cysteine-rich domains (CRD). These receptors usually bind ligands as trimers to function as receptors. The above functions are mediated by at least one cysteine-rich proligand assembly domain. Members of the TNFR superfamily, including TRAIL receptor 1, CD40, TNFR1 and TNFR2, all have this association function. Other TNFR superfamily members such as Fas, LTβR, HVEM, RANK, CD40, CD30, CD27, OX40, and DR4 all contain pre-ligand assembly domains. [0003] It was found that PLAD is necessary and sufficient for the formation of receptor aggregates in the absence of ligands. Although PLAD is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/715A61K38/17A61K47/48A61P19/02A61P29/00
Inventor 姚文兵曹进孟芳田浤高向东
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com